Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Yamashita Healthcare Holdings Ltd. (9265:JPX), powered by AI.
Yamashita Healthcare Holdings Ltd. is currently trading at ¥3,000. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Yamashita Healthcare Holdings Ltd. on Alpha Lenz.
Yamashita Healthcare Holdings Ltd.'s P/E ratio is 12.0.
“Yamashita Healthcare Holdings Ltd. trades at a P/E of 12.0 (undervalued) with modest ROE of 7.0%.”
Ask for details →Yamashita Healthcare Holdings Ltd. is a distinguished entity within the healthcare sector, primarily focusing on the development and management of medical facilities and related services. The company's primary objective is to provide comprehensive healthcare solutions through its chain of hospitals, clinics, and specialty care centers, which cater to a diverse patient population. Yamashita Healthcare Holdings is recognized for its commitment to incorporating cutting-edge medical technologies and fostering innovation in patient care methodologies. Serving key sectors such as general medicine, surgical care, and specialized treatment areas, the company plays a vital role in enhancing healthcare accessibility and quality. In the broader financial market, Yamashita Healthcare Holdings Ltd. is notable not only for its operational impact on the healthcare industry but also for its influence on healthcare-related investment activities. Headquartered in a strategic location, the company continually seeks to expand its footprint through strategic acquisitions and partnerships, aligning with global health trends and demographic shifts.
“Yamashita Healthcare Holdings Ltd. trades at a P/E of 12.0 (undervalued) with modest ROE of 7.0%.”
Ask for details →Yamashita Healthcare Holdings Ltd. (ticker: 9265) is a company listed on JPX in the Healthcare sector (Medical Distribution). It has approximately 613 employees. Market cap is $7.4B.
The current price is 3,000 with a P/E ratio of 12.03x and P/B of 0.83x.
ROE is 7.03% and operating margin is 1.31%. Annual revenue is $64.5B.